Founded with a mission to support biopharmaceutical and chemistry-based technology companies, NJ Biopharmaceuticals (NJ Bio) is a Contract Research Organization (CRO) that specializes in providing comprehensive chemistry and biology services. The company focuses on delivering affordable, timely, and customizable solutions to meet a wide range of discovery and development research needs. NJ Bio's core offerings include expertise in Antibody-Drug Conjugates (ADCs), among other specialized biopharmaceutical services, catering primarily to early-stage biotech firms.
NJ Bio has garnered positive testimonials for its ability to meet stringent timelines and deliver high-quality results, particularly in the ADC field. The company's impact is reflected in its ongoing collaborations with various biopharmaceutical companies, aiding them in both in vitro and in vivo studies. While specific investors or notable affiliated individuals are not detailed, NJ Bio's reputation for reliability and expertise underscores its significant role in advancing biopharmaceutical research and development.
